Annals of the Rheumatic Diseases
Fecha de publicación: July 15, 2020.
Autores: Samy Hakroush, Jonas Franz, Jörg Larsen, Peter Korsten, Martin Sebastian Winkler, Björn Tampe
Background: In the pandemic of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) disease 2019 (COVID-19), patients with immunosuppressive therapies have a potentially more severe course of the disease. While recent data from the registry of the Global Rheumatology Alliance have been reassuring regarding the use of biological disease-modifying antirheumatic drugs (bDMARDs), no definite recommendations can be made regarding specific bDMARDs. In their recent letter, Nuño and coworkers describe a large cohort of 122 patients with rheumatic diseases. Most interestingly, higher hospitalisation rates and more severe and life-threatening cases of COVID-19 have been described with the use of rituximab (RTX). To the best of our knowledge, we here describe the first reported case with repeated false-negative tests and a delayed diagnosis of COVID-19 in a patient with granulomatosis with polyangiitis (GPA) under maintenance therapy with RTX and concomitant influenza pneumonia.Leer más